Annual report pursuant to Section 13 and 15(d)

Combined and Consolidated Balance Sheets

v3.20.2
Combined and Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2020
Mar. 31, 2019
Current assets:    
Cash $ 100,571 $ 6,985
Prepaid expenses 5,460 2,632
Income tax receivable 36 49
Value-added tax receivable 3,009 2,913
Total current assets 109,076 12,579
Property and equipment, net 65 54
Deferred offering costs 246 1,195
Total assets 109,387 13,828
Current liabilities:    
Accounts payable 1,190 206
Accrued expenses 10,938 6,225
Due to Roivant Sciences Ltd. 3,190 58
Total liabilities 15,318 6,489
Commitments and contingencies (Note 11)
Stockholders' equity:    
Preferred stock value [1]  
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 56,455,376 shares issued and 54,655,376 shares outstanding at March 31, 2020 and 489,066,238 shares authorized, 38,590,381 shares issued and outstanding at March 31, 2019 [1] 5 4
Common stock subscribed [1]   (3)
Additional paid-in capital [1] 185,306 31,830
Accumulated other comprehensive (loss) income [1] (16) 346
Accumulated deficit [1] (91,226) (24,838)
Total stockholders' equity [1] 94,069 7,339
Total liabilities and stockholders' equity 109,387 13,828
Series A Preferred Stock [Member]    
Stockholders' equity:    
Preferred stock value [1]
[1] Retroactively restated for the reverse recapitalization as described in Note 1.